Duke-NUS Medical School, Singapore’s research-intensive, graduate-entry medical school, has joined BioStrategy Partners Inc. (BioSP), a consortium of academic institutions that collaborate with industry partners to scale academic discoveries and bring new treatments, diagnostics and other products to patients worldwide.
Other consortium members include the Children’s Hospital of Philadelphia, The Pennsylvania State University, Temple University, Thomas Jefferson University, The Wistar Institute and University of the Sciences. Duke-NUS is the consortium’s first non-US-based member.
As a member of the consortium, Duke-NUS will participate in BioSP’s Germinator program, which partners with pharmaceutical and medical device companies to identify and de-risk promising academic projects through a coordinated process, including organized sessions with industry-based scientific and commercial experts. The result is a joint development plan and funding, as well as intellectual exchanges and other forms of engagement with industry-based scientists.
“BioSP is excited to welcome into the consortium Duke-NUS, which has established a solid reputation for world-class research. Our members, industry partners and, ultimately, patients stand to benefit from the multinational perspective Duke-NUS will bring,” said Erika Swift, President of BioSP.
“Finding mechanisms to create long-term, substantive relationships with industry is a key strategy for Duke-NUS’s innovation and entrepreneurship program,” said Associate Professor Christopher Laing, Senior Associate Dean for Innovation and Entrepreneurship at Duke-NUS. “Universities are great at discovery – but we need industry partners to scale our impact. Organisations like BioSP help us to amplify our collaborative reach.”
In addition to participating in the Germinator programme, BioSP consortium members, which collectively perform more than US$1 billion of annual biomedical research and development, share best practices and expertise for commercialization, and provide shared educational resources to scientists across their institutions.
About Duke-NUS Medical School
Duke-NUS is Singapore’s flagship graduate entry medical school, established in 2005 with
a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted ‘Clinicians Plus’ poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five signature research programmes and nine centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore’s largest healthcare group. This strategic alliance has spawned 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives.
For more information, please visit www.duke-nus.edu.sg
For media inquiries, please contact:
Michele Washko
admin@biostrategypartnes.org
Tel: 717-514-0436
